Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the first nasal spray flu vaccine, upcoming disease awareness campaigns and more. NEW YORK, Sept. 27, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, Sept. 23-27, 2024. Photo provided by ASICS. FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration The U.S. Food and Drug Administration (FDA) approved FluMist for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. The vaccine is sprayed into the nose and has been used safely and effectively for many years. Nearly Two-Thirds of Americans Fear Medicare Will Not Be There When They Need It "Concerns about the future of Medicare are adding another layer of uncertainty for Americans as they consider how they'll manage health care costs in retirement," said Kristi Martin Rodriguez, senior vice president of the Nationwide Retirement Institute. "With high living costs already squeezing household budgets, many are worried about having enough saved to cover their long-term health care." Cardinal Health to Acquire Integrated Oncology Network, a Physician-Led Independent Community Oncology Network The transaction demonstrates Cardinal Health's continued investment in specialty and oncology, adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states. ADHD Redefined: ADDitude Honors ADHD Empowerment Month with Groundbreaking Campaign Throughout October, ADDitude will highlight a new definition of ADHD each day, sharing inspiring stories of readers who have contributed their personal experiences. The campaign will also feature exclusive profiles of prominent figures in the ADHD community, including novelist Rebecca Makkai, stand-up comedian Rachel Feinstein, and illustrator Hayley Wall, who explain how ADHD shaped their creativity and careers. Halle Berry's Respin and Menopause Pioneer Joylux Announce Strategic Partnership to Advance Intimate Health & Wellness Halle Berry is a passionate advocate for women's health, especially concerning menopause. The collaboration marks a significant milestone for Respin and Joylux as they work together to destigmatize the taboo of intimate health with science-backed solutions that empower women to take control of their health. Hear Powerful Stories of Individuals Living with Familial Hypercholesterolemia in ABC's "Family Heartbeats Unmasked" The new campaign from the Association of Black Cardiologists (ABC) is dedicated to raising awareness about Familial Hypercholesterolemia (FH), a genetic condition that significantly increases the risk of early heart disease and is often underdiagnosed, especially in Black Americans and other minority populations. Flex Confirms Period Discs and Cups Are Free from Harmful Metals and PFAS Amid Concerns Over Toxic Chemicals in Tampons Flex announced that independent third-party lab testing confirmed all Flex menstrual discs and cups are free from harmful PFAS (forever chemicals), lead, arsenic, cadmium, and mercury. This follows the FDA's recent decision to investigate toxic metals found in tampons, fueling discussions about the need for more research and innovation in menstrual health. Brian Cox Warns the World About Workplace Mental Health Threat in PSA for ASICS In the PSA, Brian Cox plays the role of the world's scariest boss to highlight the silent threat to our mental health—the desk we work at every day. The PSA calls on office workers to put their mental health first by taking a Desk Break, a short movement break, during the working day. WebMD Announces 2024 Health Heroes: Visionaries Leveraging AI in Medicine "Artificial Intelligence is reshaping healthcare in profound ways, saving lives and improving patient outcomes," said Dr. John Whyte, Chief Medical Officer of WebMD. "This year's Health Heroes are leading the way in AI innovation, and we are honored to recognize their achievements." Bosley and Lumenis Partner to Introduce Breakthrough Hair Loss Solution, FoLix™, to the U.S. The partnership initiates a new era in hair loss treatment by introducing the first FDA-cleared fractional laser solution for hair loss to U.S. customers for the first time, potentially transforming the lives of millions of people affected by hair loss in the U.S. NYU Langone Health Forms New Partnership to Minimize Deaths from Extreme Heat Amid Rising Global Temperatures Project HEATWAVE (Heat Emergency Avoidance Technologies Working to Adapt to Vulnerabilities Equitably), according to its founders, will be the first-ever initiative to combine advanced climate modeling, public health analysis and policy, and medical and technology innovation to study and help reduce heat-related mortality due to climate change. October is Raynaud's Awareness Month Raynaud's phenomenon is a disorder that affects blood vessels, primarily in the fingers and toes, causing them to constrict in response to cold temperatures or stress. This loss of blood flow can result in episodes of numbness, tingling, and color changes in the affected areas. Seelos Therapeutics Announces the Signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to Evaluate SLS-002 for Treatment of PTSD "Approximately 13 million people in the U.S. live with PTSD and there have been no new drugs approved in the last two decades for people suffering the effects of PTSD," said Raj Mehra, Ph.D., Chief Executive Officer of Seelos. "I believe that the inclusion of SLS-002 in this study is due to the robust amount of anecdotal evidence that ketamine has the potential to be an effective therapeutic for the symptoms of PTSD and other related conditions." For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The US Food and Drug Administration (US FDA) has approved FluMist for self- or caregiver-administration. FluMist is approved for preventing influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. FluMist is sprayed into the nose and has been used safely and effectively for many years. It was initially approved by the FDA in 2003 for use in individuals 5 through 49 years of age, and in 2007, the FDA approved the use of FluMist to include children 2 through 5 years of age. It is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a health care provider. "Today's approval of the first influenza vaccine for self- or caregiver administration provides a new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility and accessibility for individuals and families," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "Getting vaccinated each year is the best way to prevent influenza, which causes illness in a substantial proportion of the U.S. population every year and may result in serious complications, including hospitalization and death. This approval adds another option for vaccination against influenza disease and demonstrates the FDA's commitment to advancing public health." FluMist contains a weakened form of live influenza virus strains and is sprayed in the nose. A prescription is still required to receive FluMist. There are now two approved options for receiving FluMist. The vaccine may be administered by a health care provider in a healthcare setting (including a pharmacy) or it may be administered by the vaccine recipient or a caregiver who is 18 years of age or older. The most commonly reported side effects of FluMist are fever over 100°F in children 2 through 6 years of age, runny nose and nasal congestion in individuals 2 through 49 years of age and a sore throat in adults 18 through 49 years of age. For those interested in self- or caregiver-administration, the vaccine manufacturer plans to make the vaccine available through a third-party online pharmacy. Those who choose this option will complete a screening and eligibility assessment when they order FluMist. The third-party pharmacy determines eligibility based on the completed screening and, if it is determined that the intended vaccine recipient is eligible, the pharmacy writes the prescription and ships the vaccine to the address provided by the individual who placed the order. The vaccine can then be administered to the prescribed household member(s) at their convenience. Vaccine recipients and caregivers who administer FluMist will be sent the vaccine, the Prescribing Information, Information for Patients and their Caregivers and Instructions for Use. The Instructions for Use provides detailed instructions for storage, administration and disposal of FluMist. The FDA granted this approval of FluMist (Influenza Vaccine Live, Intranasal) to MedImmune LLC.